Illumina Inc (ILMN) Stock Price, Quote & News

Company Profile

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other g...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 858 202 4500

Fax: 858 202 4766

Website: www.illumina.com

Address:

5200 Illumina Way, San Diego, United States

CapitalMonk May. 6 at 6:13 PM

$ILMN Price: $141.57 (+1.80%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±1.48% RSI: 60.1 | Momentum: Strong Momentum Volume: -61.1% vs avg Volatility: 3.13% Support: $118.30 | Resistance: $142.41 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25

0 · Reply

Stockprofiler May. 6 at 4:57 PM

$VNRX New Article. VolitionRx is stacking catalysts heading into Q4 2026 — finger-prick sepsis detection, French reimbursement, a $5M vet milestone, and licensing talks with 10 major diagnostics players. Revenue up 40%. Not financial advice. DYOR. https://allcapresearch.com/f/volitionrx-vnrx-stacking-catalysts-into-q4-2026 $EXAS $ILMN $PACB $NTRA

1 · Reply

v92 May. 5 at 3:08 AM

$ILMN Lot’s of competition these days. Wasn’t the case not long ago. I’m avoiding this one.

0 · Reply

FuegoFiesta May. 4 at 9:55 PM

$NTNX $ILMN $JAZZ $CF extension

0 · Reply

harmongreg May. 4 at 8:13 PM

looks like I filled on $ILMN May 140 calls while walking the dog,.

0 · Reply

howardlindzon May. 3 at 4:21 PM

5 ideas $FSLR $GME $IBKR $ILMN $LLY @harmongreg a fave follow

1 · Reply

harmongreg May. 3 at 4:20 PM

Dragonfly Capital - 5 Trade Ideas for Monday: First Solar, Gamestop, Interactive Brokers, Illumina and Lilly https://dragonflycap.com/5-trade-ideas-for-monday-first-solar-gamestop-interactive-brokers-illumina-and-lilly/ $FSLR $GME $IBKR $ILMN $LLY

0 · Reply

azstockguy May. 1 at 9:09 PM

$ILMN might finally be breaking out

0 · Reply

tievLeaf May. 1 at 6:26 AM

$QSI Quantum-Si is trying something crazier. READ proteins more like DNA sequencing. If Proteus delivers: direct sequence reads direct PTM mapping isoform resolution tiny sample input simpler workflow …then it attacks a weakness of MS. MS often tells you pieces of protein, then software reconstructs likely identity. Proteus aims to tell you: "this exact protein molecule looked like this, with these modifications." That is a much richer biological layer. For long-term upside → Proteus is the bigger bombshell. Reason: could create a whole new proteomics stack could democratize protein analysis like Illumina did for genomics could make parts of traditional proteomics workflow obsolete. QSI is a new science infrastructure. $ILMN $QQQ $SPY $SLS

2 · Reply

labibaouf Apr. 30 at 11:43 PM

$ILMN used to be the darling of wall street , now even on great ER report, the stock does not react.

0 · Reply

Illumina price target raised to $95 from $80 at Citi

2026-05-01T13:06:15.000Z - 7 days ago

Illumina price target raised to $125 from $120 at JPMorgan

2026-05-01T12:18:53.000Z - 7 days ago

Illumina price target raised to $155 from $150 at Evercore ISI

2026-05-01T10:49:44.000Z - 7 days ago

Illumina price target lowered to $140 from $150 at Canaccord

2026-05-01T09:31:40.000Z - 7 days ago

Illumina price target raised to $122 from $110 at Barclays

Apr 30, 2026, 4:30 PM EDT - 7 days ago

Illumina Earnings Call Transcript: Q1 2026

2026-04-30T20:26:56.000Z - 7 days ago

Illumina reports Q1 adjusted EPS $1.15, consensus $1.05

2026-04-30T20:25:31.000Z - 7 days ago

Illumina raises FY26 adjusted EPS view to $5.15-$5.30 from $5.05-$5.20

Apr 30, 2026, 4:05 PM EDT - 7 days ago

Illumina Reports Financial Results for First Quarter of Fiscal Year 2026

Apr 16, 2026, 9:15 AM EDT - 22 days ago

DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows

2026-04-14T13:44:47.000Z - 24 days ago

Illumina and D3b announce partnership for research in pediatric diseases

Apr 14, 2026, 9:15 AM EDT - 24 days ago

Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease

Apr 9, 2026, 4:30 PM EDT - 4 weeks ago

Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026

2026-04-02T13:11:15.000Z - 5 weeks ago

Illumina announces board changes

Apr 2, 2026, 9:07 AM EDT - 5 weeks ago

Illumina Announces Changes to Board of Directors

2026-03-18T13:21:59.000Z - 7 weeks ago

Labcorp, Illumina expand collaboration to broaden access to oncology testing

Mar 18, 2026, 9:15 AM EDT - 7 weeks ago

Illumina and Labcorp expand collaboration to broaden access to precision oncology testing

2026-03-16T13:20:12.000Z - 7 weeks ago

Illumina announces strategic collaboration with Veritas Genetics

Mar 16, 2026, 9:15 AM EDT - 7 weeks ago

Illumina advances preventive genomics through strategic consortium with Veritas Genetics

Mar 5, 2026, 9:15 AM EST - 2 months ago

Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering

Mar 3, 2026, 3:10 PM EST - 2 months ago

Illumina Transcript: TD Cowen 46th Annual Health Care Conference

Feb 27, 2026, 9:15 AM EST - 2 months ago

Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida

2026-02-27T13:55:17.000Z - 2 months ago

Roche genome pricing positive for Illumina, says TD Cowen

Feb 26, 2026, 8:00 AM EST - 2 months ago

Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow, Details Presented at AGBT 2026

Feb 25, 2026, 9:15 AM EST - 2 months ago

Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics

2026-02-24T17:21:30.000Z - 2 months ago

Illumina announces launch of TruPath Genome

Feb 24, 2026, 12:15 PM EST - 2 months ago

Illumina launches TruPath Genome, setting a new standard in genomic insight

Feb 23, 2026, 9:15 AM EST - 2 months ago

Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility

Feb 17, 2026, 3:10 PM EST - 2 months ago

Illumina To Webcast Upcoming Investor Conference

2026-02-09T12:07:09.000Z - 3 months ago

Illumina price target lowered to $170 from $195 at Piper Sandler

2026-02-06T14:50:24.000Z - 3 months ago

Illumina price target raised to $137 from $132 at Baird

2026-02-06T13:38:14.000Z - 3 months ago

Illumina price target raised to $135 from $120 at UBS

2026-02-06T13:28:16.000Z - 3 months ago

Illumina price target lowered to $150 from $155 at Evercore ISI

2026-02-06T12:40:48.000Z - 3 months ago

Illumina price target lowered to $120 from $130 at JPMorgan

Feb 5, 2026, 4:30 PM EST - 3 months ago

Illumina Earnings Call Transcript: Q4 2025

Feb 5, 2026, 4:06 PM EST - 3 months ago

Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025

Feb 3, 2026, 9:15 AM EST - 3 months ago

Illumina and the San Diego Zoo Wildlife Alliance partner to sequence the Frozen Zoo®, supporting critical conservation genetics efforts globally

Jan 30, 2026, 9:05 AM EST - 3 months ago

Illumina completes acquisition of SomaLogic

Jan 20, 2026, 9:15 AM EST - 3 months ago

Illumina secures CMS reimbursement for TruSight™ Oncology Comprehensive, expanding access to precision oncology

Jan 13, 2026, 10:30 AM EST - 4 months ago

Illumina Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 9:18 AM EST - 4 months ago

Illumina unveils dataset to speed up AI-powered drug discovery

Jan 13, 2026, 9:15 AM EST - 4 months ago

Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery

Jan 13, 2026, 9:00 AM EST - 4 months ago

Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025

Jan 12, 2026, 4:07 PM EST - 4 months ago

Illumina to Announce Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 5, 2026

Jan 8, 2026, 4:30 PM EST - 4 months ago

Illumina Appoints Dr. Eric Green as Chief Medical Officer

Jan 8, 2026, 8:07 AM EST - 4 months ago

Illumina and PREMIA partner to expand clinical access to CGP in Asia

Jan 6, 2026, 9:15 AM EST - 4 months ago

Illumina launches powerful software for connected, intuitive, and scalable multiomic analysis

Dec 11, 2025, 9:15 AM EST - 5 months ago

Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually

Nov 19, 2025, 9:20 AM EST - 6 months ago

Illumina Transcript: Wolfe Research Healthcare Conference 2025

Nov 12, 2025, 12:00 PM EST - 6 months ago

Illumina whole-genome sequencing provides greater insight into genetic signals behind common diseases--according to Nature study

Nov 10, 2025, 1:16 PM EST - 6 months ago

Final Trades: Morgan Stanley, Cisco Systems, Illumina and FTAI Aviation

CSCO FTAI MS

Nov 10, 2025, 12:15 PM EST - 6 months ago

Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks

LAB

Nov 5, 2025, 5:16 PM EST - 6 months ago

Illumina Responds to Positive Updates from Chinese Ministry of Commerce

Oct 30, 2025, 4:30 PM EDT - 6 months ago

Illumina Earnings Call Transcript: Q3 2025

Oct 30, 2025, 4:05 PM EDT - 6 months ago

Illumina Reports Financial Results for Third Quarter of Fiscal Year 2025

Oct 20, 2025, 4:21 PM EDT - 7 months ago

Final Trades: Illumina, Columbia Banking, Alibaba and JPMorgan Chase

BABA COLB JPM

Oct 15, 2025, 9:15 AM EDT - 7 months ago

Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights

Oct 15, 2025, 9:15 AM EDT - 7 months ago

Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot

WGS

Oct 14, 2025, 4:05 PM EDT - 7 months ago

Illumina to Announce Third Quarter 2025 Financial Results on Thursday, October 30, 2025

Oct 1, 2025, 9:05 AM EDT - 7 months ago

Illumina launches new business to accelerate technology and data-driven discovery

Sep 26, 2025, 9:40 AM EDT - 8 months ago

ILMN Stock vs. IQV Stock

IQV

Sep 23, 2025, 9:15 AM EDT - 8 months ago

Illumina advances personalized cancer care with new pharma development partnerships

Sep 18, 2025, 9:15 AM EDT - 8 months ago

Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

ALNY

Sep 3, 2025, 9:15 AM EDT - 8 months ago

Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development

LAB

Jul 31, 2025, 4:30 PM EDT - 10 months ago

Illumina Earnings Call Transcript: Q2 2025

Jul 31, 2025, 4:05 PM EDT - 10 months ago

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2025

Jul 30, 2025, 9:15 AM EDT - 10 months ago

Illumina enhances flagship assay to accelerate access to comprehensive tumor profiling

Jul 10, 2025, 4:05 PM EDT - 10 months ago

Illumina to Announce Second Quarter 2025 Financial Results on Thursday, July 31, 2025

Jul 10, 2025, 9:15 AM EDT - 10 months ago

Illumina named to TIME's World's Most Sustainable Companies list for the second consecutive year

Jun 23, 2025, 7:13 AM EDT - 11 months ago

Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy

LAB

Jun 18, 2025, 9:00 AM EDT - 11 months ago

Infinity Bio Closes $8M Series A Financing Led by Illumina Ventures to Expand Leadership in Antibody Reactome Profiling

Jun 10, 2025, 4:01 PM EDT - 11 months ago

lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics

May 29, 2025, 2:01 PM EDT - 1 year ago

Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis

May 28, 2025, 2:30 PM EDT - 1 year ago

Illumina Transcript: Bernstein 41st Annual Strategic Decisions Conference 2025

May 28, 2025, 12:22 PM EDT - 1 year ago

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

AMGN BIIB DHR GILD IBB NVS SDGR

May 28, 2025, 9:15 AM EDT - 1 year ago

Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies

CapitalMonk May. 6 at 6:13 PM

0 · Reply

Stockprofiler May. 6 at 4:57 PM

1 · Reply

v92 May. 5 at 3:08 AM

$ILMN Lot’s of competition these days. Wasn’t the case not long ago. I’m avoiding this one.

0 · Reply

FuegoFiesta May. 4 at 9:55 PM

$NTNX $ILMN $JAZZ $CF extension

0 · Reply

harmongreg May. 4 at 8:13 PM

looks like I filled on $ILMN May 140 calls while walking the dog,.

0 · Reply

howardlindzon May. 3 at 4:21 PM

5 ideas $FSLR $GME $IBKR $ILMN $LLY @harmongreg a fave follow

1 · Reply

harmongreg May. 3 at 4:20 PM

0 · Reply

azstockguy May. 1 at 9:09 PM

$ILMN might finally be breaking out

0 · Reply

tievLeaf May. 1 at 6:26 AM

2 · Reply

labibaouf Apr. 30 at 11:43 PM

$ILMN used to be the darling of wall street , now even on great ER report, the stock does not react.

0 · Reply

azstockguy Apr. 30 at 8:50 PM

$ILMN wenn$500 again. ?????

0 · Reply

Dswag225 Apr. 30 at 8:33 PM

$ILMN I mean, that is as good of a day as they could plan for earnings.. They beat forecast eps by 10% Beat Rev Up Guidance Announce 1.5b share buy back And market erases the trading day on one 15min candle after close with a weak volume bomb But their margins didn't improve, they say? Honestly think $ILMN is just getting started here

1 · Reply

StocktwitsEarnings Apr. 30 at 8:30 PM

$ILMN Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.88 up 6.02% YoY • Reported revenue of $1.09B up 4.80% YoY • For fiscal year 2026, Illumina now expects total revenue of $4.52-$4.62 billion, a $20 million increase at the mid-point versus prior guidance, and non-GAAP diluted EPS of $5.15-$5.30.

0 · Reply

HarveyToronto Apr. 30 at 8:23 PM

$ILMN increased the guidance, new share buyback! double beat. I added at 120$ today.

1 · Reply

EconomyEngine Apr. 30 at 8:15 PM

$QQQ Illumina $ILMN Q1 earnings: - Revenue: $1.09B vs $1.07B est, beat - Adjusted EPS: $1.15 vs $1.05 est, beat - Adjusted gross margin: 68.2% - Adjusted EBIT margin: 21.9% FY outlook: total revenue $4.52-$4.62B.

0 · Reply

DonCorleone77 Apr. 30 at 6:56 PM

$TWLO $FSLR $RIVN $TEAM $ILMN Some notable companies reporting after the market close, with earnings consensus Estimates: - Apple (AAPL), consensus $1.95 - Amgen (AMGN), consensus $4.77 - SandDisk (SNDK), consensus $14.62 - Western Digital (WDC), consensus $2.40 - Stryker (SYK), consensus $2.98 - Roblox (RBLX), consensus (41c) - Resmed (RMD), consensus $2.80 - MasTec (MTZ), consensus 99c - Reddit (RDDT), consensus 57c - Dexcom (DXCM), consensus 47c - Twilio (TWLO), consensus $1.27 - First Solar (FSLR), consensus $3.03 - Rivian (RIVN), consensus (63c) - Atlassian (TEAM), consensus $1.33 - Illumina (ILMN), consensus $1.06 - Roku (ROKU), consensus 33c - Clorox (CLX), consensus $1.55 - Boston Beer (SAM), consensus $1.97 - Five9 (FIVN), consensus 68c. .

0 · Reply

WaverVanir Apr. 30 at 6:55 PM

🧵 5/5 — 𝗧𝗛𝗘 𝗥𝗘𝗔𝗗 🔵 Index/ETF: $SPY put-heavy, $IWM 81% puts, $SMH 71% puts → broad hedging stacked 🟢 Mega-cap single names: NVDA/MU/MCHP/QCOM/GOOGL conviction longs intact at LEAP tenors 🟡 SPXW: massive Dec '26 call program, but data noise from afternoon CORRECTIONs ⚠️ 14:32 deep-ITM put cascade = financing structure, NOT directional bear. Don't misread. 🔥 Watch tonight: $ILMN ER after close. System said sit out. Negative Kelly. The setup into May: Single names long, indices hedged, year-end SPX upside being structured. Three views, one tape. Volatility resolves it. Process over prediction. Risk-first, always. Not financial advice. #wavervanir #volanx #optionsflow #unusualoptions

0 · Reply

WaverVanir Apr. 30 at 5:12 PM

🧬 $ILMN — EARNINGS TONIGHT, SYSTEM SAYS SIT OUT Spot $126.94 (+5.46%) into Q1 print after close. Status: 𝗡𝗼 𝘁𝗿𝗮𝗱𝗲. System gates not cleared. ━━━━━━━━━━━━━━━━━━━━ 🔬 𝗧𝗛𝗘 𝗦𝗘𝗧𝗨𝗣 𝗟𝗢𝗢𝗞𝗦 𝗕𝗘𝗔𝗥𝗜𝗦𝗛 𝗢𝗡 𝗧𝗔 🔻 Daily ascending wedge into $134-135 resistance 🔻 Weekly $155 still capping multi-year base 🔻 RSI 65, momentum mid-range not extended 🔻 Avg ER move last 5 quarters: -3.4% 🔻 Feb 5 ER: stock dropped 12.9% on a beat ━━━━━━━━━━━━━━━━━━━━ 🤖 𝗩𝗢𝗟𝗔𝗡𝗫 𝗦𝗬𝗦𝗧𝗘𝗠 𝗥𝗘𝗔𝗗 🟡 Direction: SHORT @ 27% confidence 🟡 Pattern: DOUBLE TOP -55% 🟡 Model: LSTM (acc 0.57) 🟡 P(T1 $123.56): 63% over 5 bars 🟡 P(T2 $115.18): 29% over 15 bars 🔴 EV: -0.01R | Sharpe 0.42 | 𝗞𝗲𝗹𝗹𝘆 −𝟯% Negative Kelly = sit out. That's the system policing itself. ━━━━━━━━━━━━━━━━━━━━ 📊 𝗙𝗨𝗡𝗗𝗔𝗠𝗘𝗡𝗧𝗔𝗟 𝗕𝗔𝗖𝗞𝗗𝗥𝗢𝗣 🟢 Bull case: - 20% clinical consumables growth ex-China - SomaLogic proteomics platform integrating - Billion Cell Atlas: AZN/MRK/LLY pharma deals - MOFCOM lifted China sequencer export ban - NovaSeq X placements at multi-quarter highs 🔴 Bear case: - Still on China Unreliable Entities List - 26x fwd EPS = priced for execution - NIH research funding pressure ongoing - SomaLogic dilutes EPS by $0.18 - Mid-to-high single-digit research declines ━━━━━━━━━━━━━━━━━━━━ 𝗥𝗲𝗮𝗱: Mixed thesis + binary event + negative EV = walk away. Watch the print, don't trade it. If gap-down to $115 = potential Discount-zone entry If breakout >$135 = thesis flips, look for $155 Earnings are binary. Risk-first means waiting for the data to clear before sizing up. Process over prediction. Risk-first, always. Not financial advice. #wavervanir #volanx #ILMN #genomics #earnings

0 · Reply

RunnerSignals Apr. 28 at 3:30 AM

$INVA $CLDX $DNN $ILMN $NTCT all trading above ma50/200 with neutral-positive rsi that is early repricing not trapped capital

1 · Reply

GordoHLYK13 Apr. 25 at 2:24 PM

$GH $ILMN $NEO $NTRA https://youtu.be/pT0U_SC3_G4?si=yfZDply2o9EGsWtf $NEO NeoGenomics sitting right in the sweet spot of the next oncology wave. MRD testing turns cancer care from reacting late to catching relapse early. As solid tumor use expands in colon, lung, and breast, NEO’s huge community oncology footprint gives them a monster lane to scale fast. Their RaDaR / ctDNA platform creates sticky repeat revenue because once doctors trust it for monitoring, patients stay on it long term. Add elite NGS sensitivity that pharma needs for trials, and NEO becomes more than a lab — they become the gatekeeper of treatment decisions. Bottom line: $NEO not just detecting cancer anymore… they building a recurring high-margin surveillance empire. Shark fuel. Get ready shorts!!!

2 · Reply

GordoHLYK13 Apr. 25 at 10:22 AM

$GH $ILMN $NEO $NTRA $NEO those two news drops are straight shark fuel for Tuesday. Earnings usually talk about the past… but this setup got the market focused on the future. 1. Epic Aura = Revenue Beast Mode Direct integration into Epic puts Neo right inside the biggest hospital systems. Less clicks for doctors = more test orders. That’s how volume scales fast. If management hints guidance boost Tuesday, this can rip. 2. Pre-Earnings Pop = Sharks Loading From $7.91 close to $8.11 bid… money was already stepping in. That usually means smart money expecting strong numbers or bullish outlook. 3. Perfect Timing Dropping Epic news days before earnings wasn’t random. That’s management walking into the call with momentum already built. Break $8.33 clean and this could start eyeing double digits. Strong cash flow / EBITDA talk and analysts may need to chase upgrades. Verdict: You didn’t buy dead money… you bought a catalyst stack. Epic is the fuel, earnings are the spark. Shark move.

0 · Reply

GordoHLYK13 Apr. 25 at 8:17 AM

$NEO https://youtu.be/7ItZ_w_o6eU $NEO shark move lookin smart 🦈📈 stock already poppin before Tuesday because the street sees what’s coming. $30B MRD market in play, Radar ST launch gaining traction, record revenue, 10 straight quarters positive EBITDA, and 2026 guidance leaves room for upside. This ain’t no dead biotech… they’re shifting from low-value volume to high-margin growth. If Tuesday delivers, this run could just be warming up. $NTRA $GH $ILMN

0 · Reply

Market Cap	21.57B
Revenue (ttm)	4.34B
Net Income (ttm)	850.00M
EPS (ttm)	N/A
PE Ratio	27.65
Forward PE	26.76
Profit Margin	19.57%
Debt to Equity Ratio	0.56

Volume	1,241,000
Avg Vol	1,591,870
Day's Range	N/A - N/A
Shares Out	151.30M
Stochastic %K	82%
Beta	1.42
Analysts	Sell
Price Target	$137.33